Amgen's shares have experienced a notable decline amid market turbulence.
Amgen Inc. (NASDAQ:AMGN) saw its stock price drop by 1.39% in today's trading session, closing at CA$376.20. This decline reflects broader concerns in the healthcare sector and investor sentiment impacted by rising inflation and interest rates.
Investor takeaway: Investors should be cautious as Amgen's stock faces pressure from external economic factors and competitive challenges in the biotech space.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$223.32B
P/E
25.0x
Div. yield
2.43%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
+0.04%
Beta
0.41
Analyst Price Targets
Based on 34 analysts covering AMGN · as of Oct 9, 2026
Wall Street analysts forecast AMGN stock price to fall 3.9% over the next 12 months.
Consensus
Hold3.35 / 5.00
Avg. Target
C$391.46
-3.9% Upside
Previously C$390.94 on Oct 5, 2026
Current Price
C$407.44
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
40.1%
Annualized
90-Day Vol
32.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$487.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$432.43 | C$376.50 – C$496.67 |
| 60 trading days | C$458.95 | C$377.31 – C$558.25 |
| 90 trading days | C$487.10 | C$383.21 – C$619.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Amgen's stock down 1.39% today
The stock's decline comes as inflation concerns weigh heavily on consumer sentiment and market stability.
Bull case
Amgen is making strides in innovation, with recent FDA approvals that could enhance its treatment offerings and strengthen its position in the market.
Bear case
However, increased competition from other biotech firms and ongoing economic uncertainties may pose challenges to Amgen's growth and investor confidence.
Market Context
Advertisement
Amgen's recent decline is part of a broader trend in the healthcare sector, where rising inflation and anticipated interest rate hikes are causing volatility. The Consumer Sentiment Index has dropped significantly, indicating that consumers are increasingly worried about economic conditions, which may impact healthcare spending.
Competitive Landscape
Amgen faces growing competition from other biotech firms, particularly in chronic disease management. Recent comparisons with companies like Novo Nordisk and Regeneron Pharmaceuticals highlight the challenges Amgen may face in maintaining its market share and investor confidence amidst increasing competition.
Future Outlook
While Amgen's recent FDA approvals for its treatment options may provide some optimism, the company must navigate significant competitive and economic challenges. Investors should monitor how these factors will impact Amgen's performance in the upcoming quarters.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
